STOCK TITAN

Benitec Biopharma (BNTC) Stock News

BNTC NASDAQ

Benitec Biopharma Inc. develops clinical-stage genetic medicines based on its proprietary Silence and Replace DNA-directed RNA interference platform. The company’s lead program, BB-301, is a silence-and-replace therapeutic in development for dysphagia in patients with Oculopharyngeal Muscular Dystrophy, or OPMD.

Company news primarily covers BB-301 clinical development, including Phase 1b/2a study updates, follow-up data from treated cohorts, safety and clinical-activity observations, and presentations at gene therapy and muscular dystrophy medical meetings. Benitec also issues periodic financial results and operational updates tied to its development-stage biotechnology business.

Rhea-AI Summary

Benitec Biopharma (BNTC) reported a wider first-quarter fiscal 2027 net loss alongside interim clinical results showing a 100% BB-301 responder rate. Net loss for the quarter ended September 30, 2026, was $12.925 million, versus $8.965 million a year earlier; loss per share widened to $0.26 from $0.22. Research and development expenses rose to $8.618 million from $3.370 million, while administrative expenses fell to $5.859 million from $6.433 million. Cash and cash equivalents totaled $176.368 million, down from $179.972 million at June 30.

The BB-301 results cover six low-dose and three high-dose patients with OPMD-related swallowing difficulty. No serious adverse events have occurred in treated patients to date. Benitec expects to confirm the pivotal study design in the first calendar quarter of 2027 and remains on track to begin the trial in mid-2027. It also plans to change its fiscal year-end from June 30 to December 31.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
-
Rhea-AI Summary

Benitec Biopharma (NASDAQ: BNTC) reported interim BB-301 trial results showing a 100% response rate among treated patients with OPMD-related swallowing difficulties.

The Phase 1b/2a study includes six low-dose and three high-dose patients. All low-dose patients had 12-month follow-up; one high-dose patient had nine-month data and two had three-month data. At three months, throat-emptying response rates were 67% for low dose versus 100% for high dose; functional swallowing response rates on a timed water-drinking test were 17% versus 67%. Both groups had 100% response rates on the Sydney Swallow Questionnaire and 67% for throat closing at three months. All nine patients qualified as formal responders overall. Benitec reported continued durable swallowing improvements in the low-dose group. No serious adverse events have occurred in any BB-301-treated patient to date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
-
Rhea-AI Summary

Benitec Biopharma (NASDAQ: BNTC) received formal FDA feedback following a Type C meeting concerning the planned BB-301 pivotal study. Discussions about an open-label, single-arm study, in which treatment is known and there is no separate comparison group, remain ongoing. The FDA requested additional available data, including information from the Benitec-sponsored OPMD Natural History Study.

The FDA agreed to a review timeline that would allow final study design confirmation in 1Q 2027. Benitec expects patient enrollment to begin in mid-2027 and plans to provide the requested data in the coming weeks. BB-301 is being developed for OPMD-related swallowing difficulties. Interim Phase 1b/2a results will be presented at ESGCT in Hamburg, October 27–30, 2026, covering 12-month follow-up for all six Cohort 1 patients and interim follow-up for all three Cohort 2 patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
Rhea-AI Summary

Benitec Biopharma (BNTC) reported full-year 2026 results and clinical, regulatory and cash updates for lead OPMD gene therapy BB-301.

All six patients in Cohort 1 (low dose BB-301) completed 12-month follow-up, and Cohort 2 (high dose) is fully enrolled with three patients safely treated. Clinically meaningful improvements with a favorable safety profile were seen in patient-reported and X‑ray–based swallowing measures. A Type C FDA meeting on pivotal study design was held in 3Q2026, with minutes expected in October, and interim Phase 1b/2a data will be presented at the ESGCT Congress on October 27‑30, 2026. Benitec plans to initiate a pivotal BB‑301 trial in mid‑2027.

Total operating expenses rose to $51.2 million from $41.8 million, driving a net loss of $45.5 million ($0.98 per share). Cash and cash equivalents were $180.0 million as of June 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.53%
Tags
-
Rhea-AI Summary

Benitec Biopharma (NASDAQ:BNTC) reported Q3 2026 results and BB-301 updates. Total expenses were $13.6M vs. $15.3M a year ago, with net loss $11.9M ($0.24/share) vs. $14.5M. Cash was $184.8M, expected to fund BB-301 through its pivotal study.

BB-301 Phase 1b/2a data showed durable low-dose responses up to 24 months, deep disease-modifying efficacy at high dose, and no treatment-related severe adverse events. Cohort 2 enrollment is progressing, with updated interim data and an FDA pivotal-study design meeting expected in 2H 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
-
Rhea-AI Summary

Benitec Biopharma (NASDAQ: BNTC) announced acceptance of interim clinical results from the ongoing BB-301 Phase 1b/2a first-in-human study for Oculopharyngeal Muscular Dystrophy (OPMD) for an oral presentation at ASGCT 2026.

Data include 12-month follow-up for the first four Cohort 1 completers, a 24-month follow-up for the first Cohort 1 patient, and interim results for the first Cohort 2 patient; presentation is on 05/15/2026 09:15 AM in Boston.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
Rhea-AI Summary

Seaport Therapeutics appointed Dr. Sharon Mates to its Board of Directors on April 27, 2026. Dr. Mates co-founded and led Intra-Cellular Therapies through commercialization of CAPLYTA® and its 2025 acquisition by Johnson & Johnson for approximately $14.6 billion. CAPLYTA generated > $1.5 billion in sales prior to that acquisition. Dr. Mates currently serves on the boards of Medincell and Benitec (Nasdaq: BNTC) and will advise Seaport’s neuropsychiatry programs and governance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
management
-
Rhea-AI Summary

Seaport Therapeutics (BNTC) appointed Dr. Sharon Mates to its Board of Directors on April 27, 2026. Dr. Mates co-founded Intra-Cellular Therapies, led commercialization of CAPLYTA and guided the company to a $14.6 billion acquisition by Johnson & Johnson in 2025. She brings FDA approval experience, board governance roles at Medincell and Benitec (Nasdaq: BNTC), and decades in neuropsychiatry drug development to support Seaport’s programs targeting depression, anxiety, and other neuropsychiatric disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
management
-
Rhea-AI Summary

Benitec Biopharma (NASDAQ: BNTC) will host an Industry Forum Breakfast on March 10, 2026 at the MDA Clinical and Scientific Conference to present updated clinical results for BB-301, the only clinical-stage therapeutic in development for Oculopharyngeal Muscular Dystrophy (OPMD).

Benitec CEO Jerel A. Banks, M.D., Ph.D., will detail reported, durable improvements in dysphagia symptom burden and swallowing function observed in patients treated with low and high doses of BB-301. The session is open to registered conference attendees and virtually registered participants via MDA live stream.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
none
Rhea-AI Summary

Benitec Biopharma (NASDAQ: BNTC) reported positive interim Phase 1b/2a results for BB-301 in Oculopharyngeal Muscular Dystrophy (OPMD) with dysphagia. High dose BB-301 showed larger, faster improvements versus low dose at 3 months, including ~68% SSQ reduction and multi-metric radiographic gains. Low dose responses persisted and deepened at 12–24 months. No treatment-related SAEs reported for the first high-dose patient. Results presented as a late-breaking poster at the 2026 MDA Clinical & Scientific Conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.67%
Tags
none

FAQ

What is the current stock price of Benitec Biopharma (BNTC)?

Benitec Biopharma (BNTC) last closed at $7.92.

What is the market cap of Benitec Biopharma (BNTC)?

The market cap of Benitec Biopharma (BNTC) is approximately $285.9M.